Results 1 to 10 of about 108,323 (115)

Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis [PDF]

Frontiers in Neurology, 2023
BackgroundDisease activity in multiple sclerosis (MS) is defined as presence of relapses, gadolinium enhancing lesions and/or new or enlarging lesions on MRI.
Katelijn M. Blok, Katelijn M. Blok, Joost van Rosmalen, Joost van Rosmalen, Nura Tebayna, Joost Smolders, Joost Smolders, Joost Smolders, Beatrijs Wokke, Janet de Beukelaar   +9 more
doaj   +2 more sources

Primary Progressive Multiple Sclerosis: New Therapeutic Approaches [PDF]

Neuropsychopharmacology Reports
Background and Purpose Primary progressive multiple sclerosis (PPMS) is a clinically different form of MS that causes gradual and irreversible neurological impairment from symptom onset without relapses or remissions. With a mean onset age of 37–43 years,
Morteza Rajabi, Sajjad Shafaeibajestan, Sevda Asadpour, Ghazal Alyari, Niloofar Taei, Moein Kohkalani, Ramin Raoufinia, Hamed Afarande, Ehsan Saburi   +8 more
doaj   +2 more sources

A case report of carbamazepine‐induced oropharyngeal dysphagia in a patient with primary progressive multiple sclerosis [PDF]

Clinical Case Reports, 2023
Seventy‐year‐old male with primary progressive multiple sclerosis that had a severe episode of oropharyngeal dysphagia following initiation of carbamazepine. He was being treated for trigeminal neuralgia.
Daniel Bishev, Mercedes Malone, Devon Best, Yvette Bazikian   +3 more
doaj   +2 more sources

Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic. [PDF]

Brain, 2023
Wong JK, Lin J, Kung NJ, Tse AL, Shimshak SJE, Roselle AK, Cali FM, Huang J, Beaty JM, Shue TM, Sadiq SA.   +10 more
europepmc   +2 more sources

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment

Frontiers in Neurology, 2022
Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remitting multiple sclerosis and secondary and primary progressive multiple ...
Sundararajan Jayaraman, Arathi Jayaraman
doaj   +1 more source

Clinical markers for unfavorable course of multiple sclerosis [PDF]

Анналы клинической и экспериментальной неврологии, 2023
Objective. To study possible clinical markers associated with the unfavorable course of multiple sclerosis and its transition to a progressive subtype. Materials and methods.
Mariya S. Matrosova, Galina N. Belskaya, Vasiliy V. Bryukhov, Ekaterina V. Popova, Marina V. Krotenkova   +4 more
doaj   +1 more source

Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2021
Management of patients with secondary progressive multiple sclerosis (SPMS) remains one of the most challenging tasks of modern neurology. Patients with SPMS present with more severe neurological symptoms, increased hospitalization frequency, pronounced ...
Ya. V. Vlasov, N. G. Polyarnaya, A. N. Boyko   +2 more
doaj   +1 more source

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021

Neurology and Therapy, 2023
Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary progressive MS ...
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl   +5 more
doaj   +1 more source

Primary progressive multiple sclerosis in the Polish population

Aktualności Neurologiczne, 2017
Objectives: The aim of the study was the epidemiological analysis and evaluation of selected clinical and sociodemographic factors in Polish patients with primary progressive multiple sclerosis.
Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Andrzej Potemkowski   +4 more
doaj   +1 more source

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

Journal of Neuroinflammation, 2022
There are over 15 disease-modifying drugs that have been approved over the last 20 years for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited treatment options available for progressive MS.
Emily Kamma, Wendy Lasisi, Cole Libner, Huah Shin Ng, Jason R. Plemel   +4 more
doaj   +1 more source